Table 1.
Successful Phase III Trials in Advanced HCC
| Trial | Arms | N | OS | |
|---|---|---|---|---|
| Median (months) | HR (95% CI) | |||
| First‐line | ||||
| SHARP | Sorafenib versus placebo | 299 vs. 303 | 10.7 vs. 7.9 | 0.69 (0.55‐0.87) |
| Asian‐Pacific | Sorafenib versus placebo | 150 vs. 76 | 6.5 vs. 4.2 | 0.68 (0.50‐0.93) |
| REFLECT* | Lenvatinib versus sorafenib | 478 vs. 476 | 13.6 vs. 12.3 | 0.92* (0.79‐1.06) |
| Second‐line | ||||
| RESORCE | Regorafenib versus placebo | 379 vs. 194 | 10.6 vs. 7.8 | 0.63 (0.50‐0.79) |
| CELESTIAL | Cabozantinib versus placebo | 470 vs. 237 | 10.2 vs. 8 | 0.76 (0.63‐0.92) |
| REACH‐2 | Ramucirumab versus placebo | 197 vs. 95 | 8.5 vs. 7.3 | 0.71 (0.53‐0.95) |
*
Positive study for noninferiority design.